Agreed there is a question mark over the quality of Octopus managers--Titan vct fund has been a disaster over the past couple of years
They will almost certainly have had a call with Mo yesterday and must have been reassured
I do wonder about the endgame here--possibly a takeout-someone like SGS? |
Pogue
I agree that Octopus are buying for the long term not a quick trade, but I do have to question just how good their research is when they have lost 40% of the value of their early buys. Do ,they have solid information of for future revenues or are they just averaging down on the same sort of information they lost 40% of their investment on.
Sam |
Long HVO for a quick bounce at 17.1p
I had one go earlier here when it had a big plunge down to low 20's and it didn't work. The bounce happened just abit below my go.
Second go...
There is a big buyer at 16.75p...but the chart is pants..
Cant call a bottom here yet
Might have a technical bounce though
Stop at 16.5p...if those market makers disappear off there should the bounce not happen
Firmer price moves needed to call a bottom
Firmer bottoms indeed
All imo
DYOR |
Big chunk gone through today- see if its enough to turn the ship around... |
Pogue
"Makes a lot of sense for them to top up at these prices as I am sure they have done more research than the vast majority of those posting here."
I believe the chairman knows more about the company than any II, PI or BB poster.
Do you agree?
The chairman dumped majority of his holding and then the entire remaining holding just 4 working days after the July TU. He sold at 28p/29p, which just happens to be Nomad's target price from a year ago.
It also happens to be around the price I mentioned over a year ago.
Coincidence?? |
I should have put “bargain”; in quotes - it was a reference to the posters that decided institutional buying at 30p was a sign of an imminent price hike!
I think they missed the implication of significant ii buying that nevertheless didn’t cause the price to rise. |
GregB
do you think Octopus would buy one month then sell the next? The size of their holding does not look like a fast in and out trade they are long term buy and hold of undervalued assets. Makes a lot of sense for them to top up at these prices as I am sure they have done more research than the vast majority of those posting here. |
Imagine where the share price would be if Octopus weren't buying. Sub 10p probably. |
Phew!! Thank goodness Octopus are still buying and not offloading. |
HVO the gift that keeps on giving. A traders dream. I can't wait until February when this share price drops to 12p. Octopus must be furious while Cathal is laughing his head off. |
Where's 1gw and his mates??
Opinions are fine but big question for 1gw and his mates...
I warned and questioned why do virtually every share ramped by 1gw/his mates (ex blnx gang) crash?
Only 1.5 weeks into 2025 and 1gw already has 3 crashed.
NTQ - down 75% last week on placing.
Polb - down 40%, after announcing tie up with HOOK.
HVO - down 40% from peak
That's following several which crashed in 2024
1gw, given you portray yourself as a well researched poster, why do virtually all your shares crash and on red flags/warnings I post?
You make a dodgy 2nd hand car salesman sound honest.
How many multiple ids do you have and why? |
LFDKMP
"Visibility and sentiment"
That's been the case for over a year. Yet you/ your mates were ramping these suggesting great future, cash and IIs buying.
Ramping, over playing the visibility and sentiment game.
Obviously you haven't sold a single share and have been taking advantage and loaded up on the way down from 30p!!!
sikhthetech - 03 Jan 2024 - 11:59:03 - 5779 of 8910 hVIVO plc - HVO
If I traded these this time, I would be saying I've sold.
I traded trmr, whilst maintaining a negative stance. Sold them at 844p.
I traded Byot, whilst maintaining a negative stance. Sold them at 8p
Traded both because the gang and their multiple ids were pumping/dumping them.
Let's see if sell at 26.6p is another good call.
Nomad target price 29p.
Huge options held by CEO
Lack of significant revenue growth, despite the new facility.
Declining cash
NO evidence of significant buying by Institutions.
No evidence of Institutions holding > 3%
Lots of small trades to push the share price higher.
This is being talked up |
Not sure it was a bargain at 30p to be honest. Looking quite miserable at the moment. Sentiment is rock bottom. Long term holders of HVO and POLB must be kicking themselves for not cashing last summer. |
Well its now twice the bargain it was at 30p. |
My thoughts exactly, 2024 in the bag and 2025 only 13 days in. Surely no one spends millions moving premises with greater capacity for no reason. |
As I predicted then.
Getting close to that 10p, I predicted.
It's not a coincidence that this thread goes quiet and FAB busy and vice versa. P&d.
Brutally pumped up, Brutally dumped by ex-blnx gang. |
It's been atrociously managed by Mo...... |
Visibility and sentiment. |
No one seems to be taking the update in the 10th December RNS at face value. What do you think has changed in the last month? Is the perception now that the outlook for 2025 is going to be significantly worse than the 2024 figures? |
It's been a brutal selloff.
How bad are 2025 numbers going to be?
There is no way they can beat 2024 numbers |
 So about 6 months behind the timeline, I wonder if the client is still onboard? There has been a lot of news about hMPV recently...
"28/06/2023 7:00am
UK Regulatory
Hvivo (LSE:HVO)
RNS Number : 1072E
hVIVO PLC
28 June 2023
hVIVO plc
("hVIVO" or the "Company")
hVIVO to develop human metapneumovirus (hMPV) challenge model
First client of the new hMPV model secured
hVIVO plc (AIM & Euronext: HVO) , (formerly Open Orphan plc) a rapidly growing specialist contract research organisation and world leader in testing infectious and respiratory disease products using human challenge clinical trials, is developing a human metapneumovirus (hMPV) challenge model. hVIVO has signed an agreement with a North American biopharmaceutical company to manufacture a hMPV virus and conduct a characterisation study, with the intent to conduct a subsequent hMPV challenge trial in 2024 to test the efficacy of its vaccine candidate.
hVIVO will commence Good Manufacturing Practice (GMP) compliant virus manufacturing activities immediately and this is expected to complete in H1 2024. The Company will then conduct a characterisation study to identify a safe and infectious dose of wild-type hMPV in up to 36 healthy adult volunteers. Dependent on the successful completion of the characterisation study and receipt of relevant regulatory approvals, the Company expects to conduct hMPV challenge trials from H2 2024. The majority of the revenue from this end-to-end human challenge service will be recognised in 2024.
The client intends to utilise the efficacy data from the challenge study to define the endpoints for its hMPV vaccine candidate's clinical development programme, as well as providing a greater understanding of virus progression, aiding dosing decisions and confirming previous animal study results. This will allow the client to streamline future trials and make critical go/no-go decisions more quickly, therefore accelerating the development of the vaccine candidate.
hMPV is a common virus that causes an upper respiratory infection, similar to the common cold. Symptoms include cough, fever, nasal congestion, and shortness of breath. Most people have mild cases of hMPV, but severe cases can result in bronchiolitis, bronchitis and pneumonia. hMPV is associated with approximately 20% of respiratory tract infections in children worldwide(1) . Up to 16% of the children infected with hMPV develop more severe symptoms(2) , with over 16,000 deaths worldwide in children under the age of five each year.(3) Despite its prevalence and potential severity, there are currently no vaccines or antivirals approved to treat hMPV.(4)
Yamin 'Mo' Khan, Chief Executive Officer of hVIVO, said: "We are delighted to be developing the industry's first commercial hMPV human challenge model. The continued expansion of our challenge model portfolio aligns with our mission to deliver today's healthcare by empowering tomorrow's innovation. We hope to help our client to bring their treatment to patients faster through the utilisation of a new unique human challenge model. We will continue to expand our library of challenge models and provide a mechanism for our customers to expedite their drug development."
Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, said: "hVIVO's unique expertise and world leading capabilities enables us to provide our clients with a full human challenge service offering, including the development of bespoke challenge models. As demonstrated with RSV, hVIVO can also play a vital role in speeding up drug development for hMPV, which currently has no approved vaccine or antiviral treatment." |
I'm sorry but the first news of 2025 needed to be a contract. |
hVIVO successfully completes pilot characterisation study for hMPV, prepares for challenge trialshttps://youtu.be/eTkrPKIr-h0 |
Good news from the company today. More bricks in place:
Dr Andrew Catchpole, Chief Scientific Officer of hVIVO plc, said: "The pilot hMPV characterisation study in healthy volunteers was designed to test the feasibility of this new model and has been very successful, producing good infectivity rates and clear disease symptoms. Like the hVIVO RSV models, I am confident our hMPV model can play a crucial role in speeding up the development of a first vaccine or antiviral for this global pathogen, which is currently causing particular concern in China1 where a surge in cases has been recorded." |
hope this is significant- seerns today |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
